(1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine 98%

The legacy of  Supreme Drugs Pvt Ltd (SDPL) is pharmaceutical innovation and research based organization. Established in 2018 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent.

The Private limited organization is manufactures and markets generic pharmaceutical products across the globe.
With an emphasis on innovation and technology, the company has established a state-of-the-art research facility including API’s development,  formulation research, and Excipients  facility at Palanpur,  Gujarat, India. Additionally, Supreme Drugs Pvt Ltd, Palanpur, Gujarat has invented Inhalation remedy for respiratory virus as well as  COVID-19 virus treatment  and the development is joint ventured with Dr. Keshav Deo, Life Activus Pvt Ltd, Hydrabad, India.

As a growth strategy, the company has aggressively started development for  international generics market with the support to  ANDA and DMF filings. Supreme Drugs Pvt Ltd has also filings across Canada, Europe, Australia, South Africa & Brazil. The company caters to the rest of the world markets through branded API’s, Excipients and formulation sales.

The company aims to explore opportunities in the therapeutic areas such as antiviral, antibiotics and respiratory diseases. SDPL also has  co-promoted a company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of  inflammation, autoimmune diseases and metabolic disorders.